Press release from Companies
Publicerat: 2024-07-31 11:10:13
CS MEDICA Approves Key Proposals at Extraordinary General Meeting
CS MEDICA (”CS MEDICA” or “The Company”) is pleased to announce the successful approval of several key proposals at its Extraordinary General Meeting (EGM) held on July 31, 2024. The approved resolutions are as follows:
The total number of votes as of the date of this Statement is 12,322,635, of which 71.8%, equal to 8,842,160 votes, were represented at the EGM. The resolutions were approved unanimously by all shareholders represented at the EGM.
For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/
CS MEDICA A/S, a Danish MedTech pioneer, specializes in developing evidence-based, CBD-integrated treatments for pain management, autoimmune and stress-related disorders. With a focus on patient-centric care, our products range from innovative R&D to registered over-the-counter substance-based medical devices and dermaceuticals. Our flagship CANNASEN® brand, alongside our own-label solutions, exemplifies our dedication to safe, high-quality treatments for both human and veterinary health globally.
The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com and LinkedIn.
CANNORDIC A/S, a subsidiary of CS MEDICA Group, is a pioneering MedTech company specializing in innovative substance-based medical devices containing bioactive CBD. Our dedication to enhancing lives by integrating innovation, science, technology, and natural cannabis compounds positions it as a pioneer in the medical technology industry. The company ensures robust research, development, manufacturing, compliance, data insights, and commercialization processes.